Literature DB >> 372063

Double-blind comparison of cimetidine and placebo in the maintenance of healing of chronic duodenal ulceration.

K D Bardhan, D M Saul, J L Edwards, P M Smith, S J Haggie, J H Wyllie, H L Duthie, I V Fussey.   

Abstract

Patients suffering from chronic duodenal ulceration were allocated at random to treatment with either cimetidine (400 mg twice daily) or matching placebo for six months. Before entry to the trial all patients were shown to have healed ulcers on endoscopy. Most of the patients had participated in a one-month trial of cimetidine during which their ulcers healed. The trial showed that four of 29 patients relapsed on maintenance treatment with cimetidine, which therefore did not confer complete immunity from relapse. However, cimetidine treatment was very much better than placebo treatment, on which 18 of 31 patients relapsed. Of the 22 patients who relapsed clinically, 20 were submitted to endoscopy and 19 of these were shown to have ulcerated again. Endoscopy at the end of the trial showed that ulcers had also redeveloped in five of 28 asymptomatic patients. Length of previous dyspeptic history had no bearing on the results of the trial but there was evidence that relapse on placebo was less likely if the ulcer had originally healed on a high dose of cimetidine. Clinical relapse was associated with worsening duodenitis. Symptoms, clinical observation, and laboratory tests showed no important abnormalities in the patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 372063      PMCID: PMC1419437          DOI: 10.1136/gut.20.2.158

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Long-term treatment with cimetidine in duodenal ulceration.

Authors:  K D Bardham; A Blum; G Gillespie; W Larkworthy; R Mekel; M Moshal; P M Smith; C W Venables; J H Van Tongeren; A Walan
Journal:  Lancet       Date:  1977-04-23       Impact factor: 79.321

2.  Long-term effects and after-effects of treatment of duodenal ulcer with metiamide.

Authors:  J H Saunders; K G Wormsley
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

3.  Prophylactic effect of cimetidine in duodenal ulcer disease.

Authors:  E Gudmand-Høyer; K B Jensen; E Krag; J Rask-Madsen; I Rahbek; S J Rune; H R Wulff
Journal:  Br Med J       Date:  1978-04-29

4.  Cimetidine treatment of duodenal ulceration: short term clinical trial and maintenance study.

Authors:  D J Hetzel; P J Hansky; D J Shearman; M G Korman; R Hecker; G J Taggart; R Jackson; B W Gabb
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

5.  Long term cimetidine in the management of severe duodenal ulcer dyspepsia.

Authors:  G R Gray; I S Smith; I Mackenzie; G Gillespie
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

6.  Oral cimetidine in severe duodenal ulceration. A double-blind controlled trial.

Authors:  G R Gray; I S Smith; I McKenzie; G P Crean; G Gillespie
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

7.  Cimetidine in the treatment of active duodenal and prepyloric ulcers.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

8.  Cimetidine in duodenal ulcer. Controlled trial.

Authors:  W S Blackwood; D P Maudgal; R G Pickard; D Lawrence; T C Northfield
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

9.  Maintenance treatment of recurrent peptic ulcer by cimetidine.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1978-02-25       Impact factor: 79.321

  9 in total
  10 in total

Review 1.  Current therapy in peptic ulcer.

Authors:  I N Marks
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

2.  Cimetidine and duodenal ulcer: a study of initial and low dosage maintenance treatment in Ireland.

Authors:  J M Walters; P Crean; D Kelly; P Cahill; D S Cole; M Whelton; D Weir; C F McCarthy
Journal:  Ir J Med Sci       Date:  1980-07       Impact factor: 1.568

3.  Intermittent treatment of duodenal ulcer with cimetidine.

Authors:  K D Bardhan
Journal:  Br Med J       Date:  1980-07-05

4.  Cimetidine or propantheline combined with antacid therapy for short-term treatment of duodenal ulcer.

Authors:  H O Adami; O Björklund; L K Enander; S Gustavsson; L Lööf; A Nordahl; A Rosén
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

5.  Prognosis of chronic duodenal ulcer: a prospective study of the effects of demographic and environmental factors and ulcer healing.

Authors:  R W Nasiry; J H McIntosh; K Byth; D W Piper
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

6.  Incompletely and completely healed duodenal ulcers' outcome in maintenance treatment: a double blind controlled study.

Authors:  P Paoluzi; G Ricotta; F Ripoli; F Proietti; E Zaccardelli; R Carratù; A Torsoli
Journal:  Gut       Date:  1985-10       Impact factor: 23.059

7.  Cimetidine vs placebo in duodenal ulcer therapy. Six-week controlled double-blind investigation without any antacid therapy.

Authors:  M J Collen; M R Hanan; J A Maher; M Rent; S E Stubrin; J F Arguello; L Gardner
Journal:  Dig Dis Sci       Date:  1980-10       Impact factor: 3.199

8.  Ranitidine and sucralfate as maintenance therapy for gastric ulcer disease: endoscopic control and assessment of scarring.

Authors:  T Takemoto; M Namiki; M Ishikawa; K Tsuneoka; S Oshiba; K Kawai; N Ogawa
Journal:  Gut       Date:  1989-12       Impact factor: 23.059

9.  Effect of fifteen months of double-blind treatment with cimetidine and placebo on peptic ulcer recurrence.

Authors:  A Danielsson; B Ek; L Steen
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study.

Authors:  W L Burland; B W Hawkins; J Beresford
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.